Welcome, Guest
Username: Password: Remember me

TOPIC: Prevalence of Resistance-Associated Substitutions in HCV

Prevalence of Resistance-Associated Substitutions in HCV 4 years 4 months ago #19177

  • LondonGirl
  • LondonGirl's Avatar
  • Offline
  • Platinum Member
  • Posts: 1366
  • Thank you received: 2124
  • Karma: 17
"This paper, which some Drs feel is important, not least for NHS patients in England" :(a leading NHS consultant).

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir

"We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection".

www.gastrojournal.org/article/S0016-5085...%2Fpubmed%2F27296509
GT1a Dec14 F2/8.7 VL 900000-2.5M
Jan16 Hepcivir-L MonkMed/Redemption
Baseline: VL 913575 Alt 76 Platelets low
Wk2 VL1157 Alt 23
DET Wk 8 VL 32 Alt19 'In the slow lane'
June16 Fibro 5.7 F0/1 LIF 1.5
Wk 11 VL<12 Alt 13 Det/Unq
Extending tx 12 wks Mylan Sofo/Dac MonkMed
Wk 14 VL <12 Det/Unq
Wk 16 VL UNDETECTED
Wk 22 + 4 Wks Sunprevir FixHepC
Wk 24 UNDETECTED Alt 13
Wk 12 post tx SVR12 Wk 26 SVR24
Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC
Last Edit: 4 years 4 months ago by LondonGirl.
The administrator has disabled public write access.
The following user(s) said Thank You: DrJames, pat1, GT2, fitz

Prevalence of Resistance-Associated Substitutions in HCV 4 years 4 months ago #19178

  • GT2
  • GT2's Avatar
  • Offline
  • Elite Member
  • Posts: 295
  • Thank you received: 970
  • Karma: 9
Good News for GT1s

Conclusions
Baseline RASs in NS5A have minimal effects on patients’ response to ledipasvir/sofosbuvir therapy. When these RASs do have effects, they could be largely overcome by extending treatment duration or through treatment intensification.

:)
1983: Hospitalised with Acute non-A, non-B Hepatitis after ICU blood transfusion 3mths earlier => HCV GT2
22/02/16: (pre-tmt) ALT 61, VL 2.48 IU/ml Hepascore 0.32 (F1/2), fatigue, brain fog, bloating (Treatment Naïve)
10/04/16: (Start tmt) Sofovir +DaclaHep (SOF + DCV) by Hetero Labs in India
09/05/16: ALT 34, VL: NOT Detected :cheer: :) , FBG 11.9 :huh:
17/6/16 FBG 5.7; PPBG (@14.22) 6.9 (@ 20.45) 7.1; BP 124/72
:) (Accu-Chek Mobile & Omron Auto BP Monitor) :)
The administrator has disabled public write access.
The following user(s) said Thank You: LondonGirl, pat1, fitz

Prevalence of Resistance-Associated Substitutions in HCV 4 years 4 months ago #19232

  • LondonGirl
  • LondonGirl's Avatar
  • Offline
  • Platinum Member
  • Posts: 1366
  • Thank you received: 2124
  • Karma: 17
Yes, good news, but good to be aware for the small % - So that those in the 'slow-lane' can know there is the option to extend treatment if necessary with generics safely via this website in time; especially if they are being treated by NHS England who are not always prescribing the recommended tx period and generally not offering any treatment extention from what I've heard.
GT1a Dec14 F2/8.7 VL 900000-2.5M
Jan16 Hepcivir-L MonkMed/Redemption
Baseline: VL 913575 Alt 76 Platelets low
Wk2 VL1157 Alt 23
DET Wk 8 VL 32 Alt19 'In the slow lane'
June16 Fibro 5.7 F0/1 LIF 1.5
Wk 11 VL<12 Alt 13 Det/Unq
Extending tx 12 wks Mylan Sofo/Dac MonkMed
Wk 14 VL <12 Det/Unq
Wk 16 VL UNDETECTED
Wk 22 + 4 Wks Sunprevir FixHepC
Wk 24 UNDETECTED Alt 13
Wk 12 post tx SVR12 Wk 26 SVR24
Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC
Last Edit: 4 years 4 months ago by LondonGirl.
The administrator has disabled public write access.
The following user(s) said Thank You: pat1, fitz
Time to create page: 0.125 seconds

Copyright © 2015-2020 FixHepC

Back to Top